Your browser doesn't support javascript.
loading
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
Ørnbjerg, Lykke Midtbøll; Rugbjerg, Kathrine; Georgiadis, Stylianos; Rasmussen, Simon Horskjær; Lindström, Ulf; Pavelka, Karel; Yilmaz, Neslihan; Favalli, Ennio Giulio; Nissen, Michael J; Michelsen, Brigitte; Vieira-Sousa, Elsa; Jones, Gareth T; Ionescu, Ruxandra; Relas, Heikki; Sanchez-Piedra, Carlos; Tomsic, Matija; Geirsson, Arni Jon; van der Horst-Bruinsma, Irene; Askling, Johan; Loft, Anne Gitte; Nekvindova, Lucie; Direskeneli, Haner; Iannone, Florenzo; Ciurea, Adrian; Fagerli, Karen Minde; Santos, Maria José; Macfarlane, Gary J; Codreanu, Catalin; Eklund, Kari; Pombo-Suarez, Manuel; Rotar, Ziga; Gudbjornsson, Bjorn; Rusman, Tamara; Østergaard, Mikkel; Hetland, Merete Lund.
Afiliación
  • Ørnbjerg LM; L.M. Ørnbjerg, MD, PhD, K. Rugbjerg, MSc, PhD, S. Georgiadis, PhD, S.H. Rasmussen, PhD, Copenhagen Center for Arthritis Research (COPECARE), Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Copenhagen University Hospital, Glostrup, Denmark; lykke.midtboell.oernbjerg@regio
  • Rugbjerg K; L.M. Ørnbjerg, MD, PhD, K. Rugbjerg, MSc, PhD, S. Georgiadis, PhD, S.H. Rasmussen, PhD, Copenhagen Center for Arthritis Research (COPECARE), Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Copenhagen University Hospital, Glostrup, Denmark.
  • Georgiadis S; L.M. Ørnbjerg, MD, PhD, K. Rugbjerg, MSc, PhD, S. Georgiadis, PhD, S.H. Rasmussen, PhD, Copenhagen Center for Arthritis Research (COPECARE), Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Copenhagen University Hospital, Glostrup, Denmark.
  • Rasmussen SH; L.M. Ørnbjerg, MD, PhD, K. Rugbjerg, MSc, PhD, S. Georgiadis, PhD, S.H. Rasmussen, PhD, Copenhagen Center for Arthritis Research (COPECARE), Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Copenhagen University Hospital, Glostrup, Denmark.
  • Lindström U; U. Lindström, MD, PhD, Department of Rheumatology and Inflammation Research, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.
  • Pavelka K; K. Pavelka, MD, PhD, Institute of Rheumatology, and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Yilmaz N; N. Yilmaz, MD, Department of Rheumatology, Demiroglu Bilim University, Istanbul, Turkey.
  • Favalli EG; E.G. Favalli, MD, PhD, Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy.
  • Nissen MJ; M.J. Nissen, MD, PhD, Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland.
  • Michelsen B; B. Michelsen, MD, PhD, Department of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, and Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway, and COPECARE, Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedi
  • Vieira-Sousa E; E. Vieira-Sousa, MD, Department of Rheumatology, Hospital de Santa Maria, CHULN, Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal.
  • Jones GT; G.T. Jones, PhD, G.J. Macfarlane, MD, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom.
  • Ionescu R; R. Ionescu, MD, PhD, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Relas H; H. Relas, MD, PhD, K. Eklund, MD, PhD, Inflammation Center, Department of Rheumatology, Helsinki University Hospital, Helsinki, Finland.
  • Sanchez-Piedra C; C. Sanchez-Piedra, MD, PhD, Research Unit, Spanish Society of Rheumatology, Madrid, Spain.
  • Tomsic M; M. Tomsic, MD, PhD, Z. Rotar, MD, PhD, Department of Rheumatology, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Geirsson AJ; A.J. Geirsson, MD, Department of Rheumatology, University Hospital, Reykjavik, Iceland.
  • van der Horst-Bruinsma I; I. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Askling J; J. Askling, MD, PhD, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Loft AG; A.G. Loft, MD, PhD, Department of Rheumatology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Nekvindova L; L. Nekvindova, MD, PhD, Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, and Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
  • Direskeneli H; H. Direskeneli, MD, Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey.
  • Iannone F; F. Iannone, MD, PhD, Rheumatology Unit, DETO, University of Bari, Italy.
  • Ciurea A; A. Ciurea, MD, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Fagerli KM; K.M. Fagerli, MD, PhD, Department of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Santos MJ; M.J. Santos, MD, PhD, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal.
  • Macfarlane GJ; G.T. Jones, PhD, G.J. Macfarlane, MD, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom.
  • Codreanu C; C. Codreanu, MD, PhD, Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania.
  • Eklund K; H. Relas, MD, PhD, K. Eklund, MD, PhD, Inflammation Center, Department of Rheumatology, Helsinki University Hospital, Helsinki, Finland.
  • Pombo-Suarez M; M. Pombo-Suarez, MD, PhD, Rheumatology Service, Hospital Clinico Universitario, Santiago de Compostela, Spain.
  • Rotar Z; M. Tomsic, MD, PhD, Z. Rotar, MD, PhD, Department of Rheumatology, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Gudbjornsson B; B. Gudbjornsson, MD, PhD, Centre for Rheumatology Research, Landspitali University Hospital, and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Rusman T; T. Rusman, MSc, Department of Rheumatology, Amsterdam UMC, VU University Medical Centre, Amsterdam, the Netherlands.
  • Østergaard M; M. Østergaard, MD, PhD, DMSc, M.L. Hetland, MD, PhD, DMSc, COPECARE, Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Copenhagen University Hospital, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Hetland ML; M. Østergaard, MD, PhD, DMSc, M.L. Hetland, MD, PhD, DMSc, COPECARE, Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Copenhagen University Hospital, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
J Rheumatol ; 50(8): 1009-1019, 2023 08.
Article en En | MEDLINE | ID: mdl-36455943
ABSTRACT

OBJECTIVE:

To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi), to assess the proportion reaching PRO "remission" across registries and treatment series, and to compare patients registered to fulfill the modified New York (mNY) criteria for ankylosing spondylitis (AS) vs patients with nonradiographic axSpA (nr-axSpA).

METHODS:

Fifteen European registries contributed PRO scores for pain, fatigue, patient global assessment (PtGA), Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Health Assessment Questionnaire (HAQ) from 19,498 patients with axSpA. Changes in PROs and PRO remission rates (definitions ≤ 20 mm for pain, fatigue, PtGA, BASDAI, and BASFI; ≤ 0.5 for HAQ) were calculated at 6, 12, and 24 months of treatment.

RESULTS:

Heterogeneity in baseline characteristics and outcomes between registries were observed. In pooled data, 6 months after the start of a first TNFi, pain score was reduced by approximately 60% (median at baseline/6/12/24 months 65/25/20/20 mm) in patients on treatment. Similar patterns were observed for fatigue (68/32/30/25 mm), PtGA (66/29/21/20 mm), BASDAI (58/26/21/19 mm), BASFI (46/20/16/16 mm), and HAQ (0.8/0.4/0.2/0.2). Patients with AS (n = 3281) had a slightly better response than patients with nr-axSpA (n = 993). The Lund Efficacy Index (LUNDEX)-adjusted remission rates at 6 months for pain/fatigue/PtGA/BASDAI/BASFI/HAQ were 39%/30%/38%/34%/35%/48% for the AS cohort and 30%/21%/26%/24%/33%/47% for the nr-axSpA cohort. Better PRO responses were seen with a first TNFi compared to a second and third TNFi.

CONCLUSION:

Patients with axSpA starting a TNFi achieved high PRO remission rates, most pronounced in those fulfilling the mNY criteria and for the first TNFi.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Espondilitis Anquilosante / Espondiloartritis / Espondiloartritis Axial no Radiográfica Límite: Humans Idioma: En Revista: J Rheumatol Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Espondilitis Anquilosante / Espondiloartritis / Espondiloartritis Axial no Radiográfica Límite: Humans Idioma: En Revista: J Rheumatol Año: 2023 Tipo del documento: Article